This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • HIV/AIDS  • Alert me on articles by topic

Roderick Go, DO; Roy Steigbigel, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Mitsuyasu et al¹ described potential immunologic and virologic effects of interleukin 2 administered to patients with moderately advanced human immunodeficiency virus (HIV) infection. While no significant differences were seen in median HIV RNA levels at 60 weeks, we were interested in earlier HIV RNA levels between week 12 and 60. In addition to promoting lymphocyte proliferation, interleukin 2 has also been shown and in fact used in vitro experiments to promote the infection of cell cultures with HIV. This raises the question of whether treatment with interleukin 2 may disrupt initial virologic control by antiretroviral therapy.

A recent report from Kuritzkes et al² suggested that the rate of decline of HIV RNA could be useful in predicting clinical trial outcomes. This study analyzed the HIV-1 RNA dynamics in patients starting a triple nucleoside-based regimen compared with that in patients starting an efavirenz-based regime. Data . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED LETTER

Interleukin 2 and HIV RNA Levels—Reply
Richard B. Pollard and for the AIDS Clinical Trials Group 328 Team
Arch Intern Med. 2007;167(19):2145.
EXTRACT | FULL TEXT  

RELATED ARTICLE

The Virologic, Immunologic, and Clinical Effects of Interleukin 2 With Potent Antiretroviral Therapy in Patients With Moderately Advanced Human Immunodeficiency Virus Infection: A Randomized Controlled Clinical Trial—AIDS Clinical Trials Group 328
Ronald Mitsuyasu, Rebecca Gelman, Deborah Weng Cherng, Alan Landay, John Fahey, Richard Reichman, Alejo Erice, R. Pat Bucy, J. Michael Kilby, Michael M. Lederman, Carol D. Hamilton, Juan Lertora, Becky L. White, Pablo Tebas, Anne-Marie Duliege, Richard B. Pollard, and for the AIDS Clinical Trials Group 328 Study Team
Arch Intern Med. 2007;167(6):597-605.
ABSTRACT | FULL TEXT